Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.

Magnaghi P, Salom B, Cozzi L, Amboldi N, Ballinari D, Tamborini E, Gasparri F, Montagnoli A, Raddrizzani L, Somaschini A, Bosotti R, Orrenius C, Bozzi F, Pilotti S, Galvani A, Sommer J, Stacchiotti S, Isacchi A.

Mol Cancer Ther. 2018 Mar;17(3):603-613. doi: 10.1158/1535-7163.MCT-17-0324. Epub 2017 Dec 13.

2.

The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.

Hu Y, Mintz A, Shah SR, Quinones-Hinojosa A, Hsu W.

Carcinogenesis. 2014 Jul;35(7):1491-9. doi: 10.1093/carcin/bgu014. Epub 2014 Jan 20.

3.

Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.

Hsu W, Mohyeldin A, Shah SR, ap Rhys CM, Johnson LF, Sedora-Roman NI, Kosztowski TA, Awad OA, McCarthy EF, Loeb DM, Wolinsky JP, Gokaslan ZL, Quiñones-Hinojosa A.

J Neurosurg. 2011 Oct;115(4):760-9. doi: 10.3171/2011.5.JNS11185. Epub 2011 Jun 24.

4.

Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.

Otani R, Mukasa A, Shin M, Omata M, Takayanagi S, Tanaka S, Ueki K, Saito N.

J Neurosurg. 2018 May;128(5):1428-1437. doi: 10.3171/2016.12.JNS161444. Epub 2017 Jul 28.

PMID:
28753115
5.

The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.

Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, Leithner A, Liegl B, Briggs TR, Bacsi K, Kindblom LG, Athanasou N, Amary MF, Hogendoorn PC, Tirabosco R, Flanagan AM.

J Pathol. 2011 Feb;223(3):336-46. doi: 10.1002/path.2818. Epub 2010 Dec 10.

PMID:
21171079
6.

EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.

Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry DH, Zuercher WJ, Turlais F, Ye H, Leite AP, Smith JA, Leithner A, Möller P, Brüderlein S, Guppy N, Amary F, Tirabosco R, Strauss SJ, Pillay N, Flanagan AM.

J Pathol. 2016 Jul;239(3):320-34. doi: 10.1002/path.4729. Epub 2016 May 31.

7.

Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications.

Yamaguchi T, Imada H, Iida S, Szuhai K.

Surg Pathol Clin. 2017 Sep;10(3):637-656. doi: 10.1016/j.path.2017.04.008. Epub 2017 Jun 29. Review.

PMID:
28797506
8.

Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines.

Karikari IO, Gilchrist CL, Jing L, Alcorta DA, Chen J, Richardson WJ, Gabr MA, Bell RD, Kelley MJ, Bagley CA, Setton LA.

J Neurosurg Spine. 2014 Sep;21(3):386-93. doi: 10.3171/2014.4.SPINE13262. Epub 2014 Jun 6.

9.

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.

Yamaoka T, Ohmori T, Ohba M, Arata S, Murata Y, Kusumoto S, Ando K, Ishida H, Ohnishi T, Sasaki Y.

Mol Cancer Res. 2017 Jul;15(7):915-928. doi: 10.1158/1541-7786.MCR-16-0482. Epub 2017 Mar 13.

10.

Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.

Liang C, Ma Y, Yong L, Yang C, Wang P, Liu X, Zhu B, Zhou H, Liu X, Liu Z.

Cancer Sci. 2019 Jan;110(1):166-179. doi: 10.1111/cas.13875. Epub 2018 Dec 19.

11.

An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.

Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, Halai D, Berisha F, Flicek P, Stemple DL, Stern CD, Wardle FC, Flanagan AM.

J Pathol. 2012 Nov;228(3):274-85. doi: 10.1002/path.4082. Epub 2012 Sep 26.

12.

Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib.

Zhang M, Taylor CE, Piao L, Datta J, Bruno PA, Bhave S, Su T, Lang JC, Xie X, Teknos TN, Mapp AK, Pan Q.

Mol Cancer Ther. 2013 Aug;12(8):1515-25. doi: 10.1158/1535-7163.MCT-12-1110. Epub 2013 May 30.

13.

Small-molecule targeting of brachyury transcription factor addiction in chordoma.

Sharifnia T, Wawer MJ, Chen T, Huang QY, Weir BA, Sizemore A, Lawlor MA, Goodale A, Cowley GS, Vazquez F, Ott CJ, Francis JM, Sassi S, Cogswell P, Sheppard HE, Zhang T, Gray NS, Clarke PA, Blagg J, Workman P, Sommer J, Hornicek F, Root DE, Hahn WC, Bradner JE, Wong KK, Clemons PA, Lin CY, Kotz JD, Schreiber SL.

Nat Med. 2019 Feb;25(2):292-300. doi: 10.1038/s41591-018-0312-3. Epub 2019 Jan 21.

14.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W.

Cancer Discov. 2012 Oct;2(10):922-33. doi: 10.1158/2159-8290.CD-12-0108. Epub 2012 Sep 5.

15.

Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study.

Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG, Brüderlein S, Möller P, Leithner A, Liegl B, Amary FM, Athanasou NN, Hogendoorn PC, Mertens F, Szuhai K, Flanagan AM.

J Pathol. 2011 Feb;223(3):327-35. doi: 10.1002/path.2816. Epub 2010 Nov 24.

PMID:
21171078
16.

Liposome-Protamine-DNA Nanoparticle-Mediated Delivery of Short Hairpin RNA Targeting Brachyury Inhibits Chordoma Cell Growth.

Hu Y, Singh R, Deng Z, Mintz A, Hsu W.

J Biomed Nanotechnol. 2016 Oct;12(10):1952-61.

PMID:
29360338
17.

Erlotinib inhibits growth of a patient-derived chordoma xenograft.

Siu IM, Ruzevick J, Zhao Q, Connis N, Jiao Y, Bettegowda C, Xia X, Burger PC, Hann CL, Gallia GL.

PLoS One. 2013 Nov 15;8(11):e78895. doi: 10.1371/journal.pone.0078895. eCollection 2013.

18.

Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.

Lin C, Lu W, Ren Z, Tang Y, Zhang C, Yang R, Chen Y, Cao W, Wang L, Wang X, Ji T.

Cancer Lett. 2016 Jul 10;377(1):1-10. doi: 10.1016/j.canlet.2016.04.023. Epub 2016 Apr 18.

PMID:
27090738
19.

From notochord formation to hereditary chordoma: the many roles of Brachyury.

Nibu Y, José-Edwards DS, Di Gregorio A.

Biomed Res Int. 2013;2013:826435. doi: 10.1155/2013/826435. Epub 2013 Mar 31. Review.

20.

T gene isoform expression pattern is significantly different between chordomas and notochords.

Wang K, Hu Q, Wang L, Chen W, Tian K, Cao C, Wu Z, Jia G, Zhang L, Zeng C, Zhang J.

Biochem Biophys Res Commun. 2015 Nov 13;467(2):261-7. doi: 10.1016/j.bbrc.2015.09.178. Epub 2015 Oct 3.

PMID:
26435504

Supplemental Content

Support Center